[go: up one dir, main page]

AR059742A1 - Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol - Google Patents

Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol

Info

Publication number
AR059742A1
AR059742A1 ARP070100903A ARP070100903A AR059742A1 AR 059742 A1 AR059742 A1 AR 059742A1 AR P070100903 A ARP070100903 A AR P070100903A AR P070100903 A ARP070100903 A AR P070100903A AR 059742 A1 AR059742 A1 AR 059742A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical formulations
dihydroxifenil
anhydra
vinil
benzoxazol
Prior art date
Application number
ARP070100903A
Other languages
English (en)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38475768&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059742(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR059742A1 publication Critical patent/AR059742A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente está dirigida a formulaciones farmacéuticas de una forma cristalina anhidra de un modulador de un receptor estrogénico, y composiciones farmacéuticas y procedimientos para la preparacion de éstas.
ARP070100903A 2006-03-06 2007-03-05 Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol AR059742A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77984806P 2006-03-06 2006-03-06

Publications (1)

Publication Number Publication Date
AR059742A1 true AR059742A1 (es) 2008-04-23

Family

ID=38475768

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100903A AR059742A1 (es) 2006-03-06 2007-03-05 Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol

Country Status (5)

Country Link
US (1) US20070208069A1 (es)
AR (1) AR059742A1 (es)
PE (1) PE20080117A1 (es)
TW (1) TW200800179A (es)
WO (1) WO2007103873A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080241234A1 (en) * 2006-11-21 2008-10-02 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080176914A1 (en) * 2006-11-21 2008-07-24 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080132554A1 (en) * 2006-11-21 2008-06-05 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080146630A1 (en) * 2006-11-21 2008-06-19 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175901A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of a crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080139633A1 (en) * 2006-11-21 2008-06-12 Wyeth Crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20090239920A1 (en) * 2006-11-21 2009-09-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
US20080175900A1 (en) * 2006-11-21 2008-07-24 Wyeth Pharmaceutical formulations of an anhydrate crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
BR112013010714A2 (pt) 2010-11-01 2024-01-16 Rib X Pharmaceuticals Inc Composição farmacêutica e uso de um composto antibiótico
WO2018167628A1 (en) 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019038584A1 (en) 2017-08-19 2019-02-28 Ftf Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof
CN112566625A (zh) * 2018-08-18 2021-03-26 夫特弗制药私人有限公司 口服剂量的化学治疗药物悬浮液
US20210308044A1 (en) 2018-08-18 2021-10-07 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
EP4330298A1 (en) * 2021-04-29 2024-03-06 Solvay Specialty Polymers Italy S.p.A. Pvdf fine powders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3437599C2 (de) * 1984-10-13 1987-04-16 Dolorgiet GmbH & Co KG, 5205 St Augustin Ibuprofen enthaltende Weichgelatinekapseln
US5468502A (en) * 1994-12-20 1995-11-21 American Home Products Corporation Ibuprofen enhancing solvent system
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US20060121110A1 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
AU2005311833A1 (en) * 2004-12-02 2006-06-08 Wyeth Formulations of substituted benzoxazoles
MX2007006565A (es) * 2004-12-02 2007-06-18 Wyeth Corp Formulaciones de benzoxazoles sustituidos.
BRPI0608689A2 (pt) * 2005-03-08 2010-01-19 Wyeth Corp composto, composiÇço, processos para preparar monoidrato e a forma de cristal, e, uso de um monoidrato ou de uma forma de cristal
PE20071043A1 (es) * 2006-02-14 2007-10-23 Wyeth Corp FORMULACIONES FARMACEUTICAS ACUOSAS QUE COMPRENDE LIGANDOS SELECTIVOS DEL RECEPTOR DE ESTROGENO ERß

Also Published As

Publication number Publication date
TW200800179A (en) 2008-01-01
WO2007103873A2 (en) 2007-09-13
US20070208069A1 (en) 2007-09-06
PE20080117A1 (es) 2008-02-22
WO2007103873A3 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
AR059742A1 (es) Formulaciones farmaceuticas de una forma cristalina anhidra de 2-(3- fluor-4- dihidroxifenil) 7- vinil-1,3- benzoxazol -5-ol
HN2007000407A (es) Compuesto de biaril eter urea
UY32640A (es) Aril-pirimidinas como inhibidoras de sintasa dfe aldosterona
ECSP13012770A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propan-2-sulfonil)-fenil]-pirimidin-2,4-diamina
UY33075A (es) Derivados de ciclohexano y usos de los mismos
EA021377B9 (ru) Модуляторы толл-подобных рецепторов
AR075291A1 (es) Proceso para la preparcion de derivados de l-alanina protegidos
MX336497B (es) Compuestos de tetrahidro-pirido-piridina y tetrahidro-pirido-pirim idina y su uso como moduladores de los receptores de c5a.
CU20110176A7 (es) Inhibidores de epoxicetona proteasa de tripéptidos cristalinos
HN2010002582A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
ECSP11011398A (es) Inhibidores de beta-secretasa
DK2246051T3 (da) Fremgangsmåde til fremstilling af oralt sig hurtigt opløsende tablet omfattende imidafenacin som aktiv bestanddel
CL2011002657A1 (es) Proceso para preparar una mezcla racemica de acidos cis- y trans-octahidro ciclopenta[c]pirrol-1-carboxilicos; compuestos intermediarios.
PA8717801A1 (es) Formulaciones farmaceuticas de una forma cristalina de monohidrato de 2-(3-fluor-4-hidroxifenil)-7-vinil-1,3-benzoxazol-5-ol
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
ECSP099565A (es) Compuesto de 2-amino pirimidina
EA201001243A1 (ru) Кристаллические формы n-[2-(диэтиламино)этил]-5-[(5-фтор-1,2-дигидро-2-оксо-3н-индол-3-илиден)метил]-2,4-диметил-1н-пиррол-3-карбоксамида и способы их получения
ECSP12011659A (es) Formulaciones orales sólidas y formas cristalinas de un inhibidor de la proteína de apoptosis
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
GT200800281A (es) Procedimiento para hacer sales de n-hidroxi-3-(4-(((2-(2-metil-1h-indol-3-il)-etil)amino)metil)fenil)-2e-2-propenamida
UY33348A (es) Compuestos de furopiridina y usos de los mismos
ITPR20070098A1 (it) Procedimento per idratare un terreno coesivo mediante elettrosmosi perimpedirne la riduzione volumetrica per disidratazione
EA201001870A1 (ru) Новые кристаллические формы рабепразола натрия
AR051043A1 (es) Forma cristalina de clorhidrato de (3-cian-1h-indol-7il)-[4-(4-fluorofenetil)-piperazin-1-il]-metanona
GT200900215A (es) Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina.

Legal Events

Date Code Title Description
FB Suspension of granting procedure